ReviewDrugs2006
Moxonidine: a review of its use in essential hypertension.
Review in Drugs, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 86 citations in OpenAlex.
- Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions.Signal transduction and targeted therapy · 2023Review
- Over-Prescription of the Imidazoline Receptor Agonists: Evidence for Restriction of the Therapeutic Indication.Therapeutic innovation & regulatory science · 2022Article
- Depleting hypothalamic somatostatinergic neurons recapitulates diabetic phenotypes in mouse brain, bone marrow, adipose and retina.Diabetologia · 2021Article
- Autonomic nervous system activity changes in patients with hypertension and overweight: role and therapeutic implications.Cardiovascular diabetology · 2021Review
- A novel imidazolinone metformin-methylglyoxal metabolite promotes endothelial cell angiogenesis via the eNOS/HIF-1α pathway.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021Article
- Late-StageAngewandte Chemie (International ed. in English) · 2019Article
- Behavioral and Cognitive Improvement Induced by Novel Imidazoline INeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2019Article
- Treatment of Hypertension in Chronic Kidney Disease.Current hypertension reports · 2018Review
- Effect of Central Sympathoinhibition With Moxonidine on Sympathetic Nervous Activity in Polycystic Ovary Syndrome-A Randomized Controlled Trial.Frontiers in physiology · 2018Article
- Preferred Fourth-Line Pharmacotherapy for Resistant Hypertension: Are We There Yet?Current hypertension reports · 2017Review
- Role of the renal sympathetic nerves in renal sodium/potassium handling and renal damage in spontaneously hypertensive rats.Experimental and therapeutic medicine · 2016Article
- Development of Hydrophilic Interaction Liquid Chromatography Method for the Analysis of Moxonidine and Its Impurities.Journal of analytical methods in chemistry · 2016Article
- Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection.Journal of pharmacy & bioallied sciences · 2013Review
- A sympathetic view of human obesity.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2013Review
- Chapter 2: Lifestyle and pharmacological treatments for lowering blood pressure in CKD ND patients.Kidney international supplements · 2012Article
- The central mechanism underlying hypertension: a review of the roles of sodium ions, epithelial sodium channels, the renin-angiotensin-aldosterone system, oxidative stress and endogenous digitalis in the brain.Hypertension research : official journal of the Japanese Society of Hypertension · 2011Review
- Central sympatholytic drugs.Journal of clinical hypertension (Greenwich, Conn.) · 2011Review
- Pharmacological profiles of alpha 2 adrenergic receptor agonists identified using genetically altered mice and isobolographic analysis.Pharmacology & therapeutics · 2009Review
- Treatment of hypertension in patients with diabetes mellitus : relevance of sympathovagal balance and renal function.Clinical research in cardiology : official journal of the German Cardiac Society · 2007Review
- Centrally acting antihypertensive agents: an update.Journal of clinical hypertension (Greenwich, Conn.) · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Moxonidine (Physiotens, Moxon, Cynt) is an orally administered imidazoline compound with selective agonist activity at imidazoline I1 receptors and only minor activity at alpha2-adrenoceptors. Moxonidine acts centrally to reduce peripheral sympathetic activity, thus decreasing peripheral vascular resistance. In patients with mild to moderate hypertension, moxonidine reduces blood pressure (BP) as effectively as most first-line antihypertensives when used as monotherapy and is also an effective adjunctive therapy in combination with other antihypertensive agents. It improves the metabolic profile in patients with hypertension and diabetes mellitus or impaired glucose tolerance, is well tolerated, has a low potential for drug interactions and may be administered once daily in most patients. Thus, moxonidine is a good option in the treatment of patients with mild to moderate hypertension, particularly as adjunctive therapy in patients with the metabolic syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.